OPKO Health acquires Prolor Biotech for $480 million
24/05/2013Prolor Biotech develops proprietary versions of proteins already approved for medical therapy, such as human growth hormone, and helps with commercialization. The Israeli biomedical company Prolor Biotech has been sold to OPKO Health for $7 a share, giving the company a value of $480 million, both companies announced Wednesday. Although a final agreement was signed, [...]
Read MoreXTL Biopharmaceuticals Files Application for Listing on the NASDAQ
04/06/2012XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the “Company”), a biopharmaceutical development company, announced today that it has filed an application for relisting its ADRs on the NASDAQ Stock Exchange. The Company and its advisors believe it currently is in compliance with the criteria for the NASDAQ listing (subject to additional qualitative criteria of the [...]
Read MoreXTL Biopharmaceuticals Ltd. Signs Letter of Intent to Acquire a Drug Development Company
30/05/2012XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (hereinafter, “XTL”), a biopharmaceutical development company, announced yesterday that on April 12, 2012, it signed a non-binding letter of intent to acquire a company (hereinafter, the “Target Company”). Pursuant to the letter, XTL intends to acquire all of the share capital of the Target Company in consideration for [...]
Read MoreProlor Biotech to raise $75m on AMEX
08/04/2012Prolor Biotech Inc. (AMEX: PBTH; TASE: PBTH) has filed with the US Securities and Exchange Commission (SEC) to raise a gross $75 million in shares in offerings. Prolor, which is developing longer-lasting versions of commercial medicines, has $13 million in cash, which it says will be sufficient at least through the end of the year. The [...]
Read More
